Bioniche Recognized as one of Canada’s Top-Ten Emerging Biotech Companies
London, Ontario, December 5, 2000 – Bioniche Life Sciences Inc., (BNC: TSE), a fully integrated Canadian biopharmaceutical company serving both the human and veterinary markets, was recognized yesterday by an independent jury as one of Canada’s top-ten corporate investment and partnering prospects in the Canadian Life Sciences sector. The investment/partnering forum was part of the 7th Annual Ottawa Life Sciences National Conference and Exhibition being held in Ottawa this week.
“Bioniche is well suited for recognition of this award by virtue of our broad infrastructure – from research to clinical development to manufacturing to international marketing – and our equally broad product pipeline based on three distinct technology platforms,” said Graeme McRae, President and CEO of Bioniche Life Sciences. “Indeed, last year alone we entered into sixteen separate licensing agreements and completed three financings. It is always an honour to be recognized for one’s achievements and potential.”
The winners of the national competition were given the opportunity to present a profile of their businesses to an audience of venture capitalists and life science investors. Mr. McRae highlighted Bioniche’s broad technology platform including MCC, the Mycobacterial cell wall-DNA complex technology now in a Phase I/II clinical trial for bladder cancer and soon to be in a Phase I study for prostate cancer; the novel anticancer Oligomodulator™ platform; as well as the E.coli cattle vaccine to treat the deadly E.coli 0157:H7 bacteria which infected thousands of people in the town of Walkerton this past spring.
The forum was part of the opening day events to launch the conference that is taking place from December 4th to 6th at the Ottawa Congress Centre. This event brings life sciences companies, researchers, experts and venture capitalists from across North America to initiate discussions and debate issues surrounding biotechnology.
About Bioniche Bioniche Life Sciences Inc. is a leading Canadian biopharmaceutical company that develops, manufactures and markets proprietary products for human and veterinary markets worldwide. The Company employs 140 people through three operating divisions: Bioniche Therapeutics, Vetrepharm Animal Health and Bioniche Pharma.
Bioniche Life Sciences Inc. trades on the Toronto Stock Exchange (TSE) under the symbol “BNC” and currently has 23,008,204 shares outstanding.
For further information, please contact: Natalie Godbout Manager, Corporate Communications Bioniche Life Sciences Inc. Toll Free: (800) 567-2028 email@example.com
Mike Polonsky Investor Relations The Equicom Group Tel: (416) 815-0700 ext. 231 Fax: (416) 815-0080 firstname.lastname@example.org